These remain good days for Swiss drug and diagnostics giant Roche (Nasdaq:RHHBY), as the company continues to see double-digit growth across most of its oncology franchise, with ongoing growth in diagnostics and early signs of additional operating leverage. While Roche's oncology pipeline looks solid, it's well worth asking if management has been too slow to move to bulk up other areas. Although Roche shares still look a little undervalued, M&A speculation is likely to remain in play for the foreseeable future, likely adding volatility to the shares.
 
Good Leverage Leads To Upside In The First Half
Although Roche's top-line results were almost exactly in line with expectations, the company still managed to beat operating assumptions by a meaningful amount due to more effective marketing leverage.
 
Revenue rose 5% (in constant currency) this quarter, led by 6% growth in the pharma business and 3% growth in the diagnostics business. Within drugs, Avastin and the company's HER2 franchise continue to grow at double-digit rates, while Lucentis was also up by double digits. Within diagnostics, Roche's professional business was up 6% (similar to Abbott (NYSE:ABT)), with double-digit growth in immunoassay. Tissue diagnostics was also pretty good (up 6%), while molecular diagnostics was weak and up only 1%. Roche's negative 5% performance in diabetes was poor, but at least better than Johnson & Johnson (NYSE:JNJ) as the major testing companies suffer through a harsher reimbursement environment.
 
SEE: Evaluating Pharmaceutical Companies

On the margin side, Roche was already a fairly strong performer. Nevertheless, marketing expense growth of just 3% allowed the company to post 10% growth in operating income (or 7% netting out pension adjustments), with pharma up 8% and diagnostics up 9%. On a margin basis, Roche outperformed the average sell-side target by 120bp.
 
Forget Alexion, But M&A Makes Sense
As I expected, Roche threw cold water on the notion of buying Alexion (Nasdaq: ALXN), the orphan drug specialist. While Alexion looked like a very expensive deal for Roche, and one with high execution risk and minimal synergies, the notion that Roche should and will do deals is sound.
 
Over 60% of the company's pharmaceutical sales come from oncology, and Roche has seen some embarrassing trial failures in areas like diabetes and cardiovascular disease in its attempts to diversify. Although there are some interesting and high-potential drugs in the pipeline (including a Glyt-1 inhibitor for schizophrenia, etrolizumab in ulcerative colitis, and crenezeumab in Alzheimer's disease), Roche would likely do well for itself by adding more heft to its non-oncology operations.

The question, though, is one of price. With the multi-year bull market in biotech having spiked valuations, there aren't many bargains left. Still, I could see Roche possibly having some interest in companies like Biogen Idec (Nasdaq: BIIB), Vertex (Nasdaq: VRTX), or other orphan drug companies were valuations to ease off over the next year or two.
 
An Attractive Pipeline Moving Forward
Roche still has an attractive pipeline of its own. Between Roche management and comments from Bristol-Myers (NYSE: BMY), it sounds as though the timeline for PDL-1 could be shorter, and GA101 looks well-positioned as a follow-on to Rituxan (a drug where biosimilar competition in Europe is starting to look like more of a threat).

SEE: The Value Investor's Handbook
 
The Bottom Line
Even with the strong performance in these shares over the past year, there still seems to be some value left. With long-term free cash flow growth in the neighborhood of 5%, a fair value in the mid-to-high $60s is reasonable. While Pfizer (NYSE: PFE) may have more upside with respect to current growth expectations, Roche remains one of the more attractive large-cap pharmaceuticals, with relatively limited patent risk and several significant pipeline/launch developments over the next 12 months.
 
Disclosure – As of this writing, the author owns shares of Roche.

Related Articles
  1. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  2. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  3. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  4. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  6. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  7. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  8. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  9. Mutual Funds & ETFs

    ETF Analysis: Schwab US Broad Market

    Take an in-depth look at the Schwab U.S. Broad Market ETF, an incredibly low-cost fund based on a wide selection of the U.S. equity market.
  10. Professionals

    Tips for Helping Clients Though Market Corrections

    When the stock market sees a steep drop, clients are bound to get anxious. Here are some tips for talking them off the ledge.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. Earnings Per Share - EPS

    The portion of a company's profit allocated to each outstanding ...
  5. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  6. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
RELATED FAQS
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. How does the role of Medicare/Medicaid affect the drugs sector in the U.S.?

    Medicare and Medicaid have enormous influence on the pharmaceutical, or drugs, sector in the United States. For instance, ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!